Top small-cap healthcare stocks surging above 200-day moving average
Seeking Alpha News (Wed, 11-Feb 2:37 PM ET)
Ocugen Appoints Rita Johnson-Greene as New Chief Financial Officer
TipRanks (Mon, 9-Feb 8:53 AM ET)
Ocugen taps Rita Johnson-Greene as CFO
Seeking Alpha News (Mon, 9-Feb 7:07 AM ET)
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
Globe Newswire (Mon, 9-Feb 7:02 AM ET)
Globe Newswire (Fri, 23-Jan 8:00 AM ET)
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
Globe Newswire (Wed, 21-Jan 8:32 AM ET)
Globe Newswire (Thu, 15-Jan 8:15 AM ET)
Globe Newswire (Tue, 13-Jan 7:00 AM ET)
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
Globe Newswire (Mon, 12-Jan 6:30 AM ET)
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
Globe Newswire (Fri, 9-Jan 7:02 AM ET)
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ocugen trades on the NASDAQ stock market under the symbol OCGN.
As of February 12, 2026, OCGN stock price was flat at $1.41 with 2,082,827 million shares trading.
OCGN has a beta of 1.38, meaning it tends to be more sensitive to market movements. OCGN has a correlation of 0.09 to the broad based SPY ETF.
OCGN has a market cap of $461.52 million. This is considered a Small Cap stock.
Last quarter Ocugen reported $2 million in Revenue and -$.07 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.02.
In the last 3 years, OCGN traded as high as $2.11 and as low as $.35.
The top ETF exchange traded funds that OCGN belongs to (by Net Assets): VTI, VXF, KOMP, ITOT, VHT.
OCGN has outperformed the market in the last year with a return of +109.8%, while the SPY ETF gained +13.8%. In the last 3 month period, OCGN beat the market returning +6.0%, while SPY returned 0.0%. However, in the most recent 2 weeks OCGN has underperformed the stock market by returning -8.4%, while SPY returned -2.0%.
OCGN support price is $1.34 and resistance is $1.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCGN shares will trade within this expected range on the day.
